Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | ITK | Q08881 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18269002 | 0.89 | FGFR2 (0.62) | BTKEGFRLCKITKFGFR1 | |
| SCHEMBL18269159 | 0.88 | TGFBR1 (0.52) | BTKFGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL18268993 | 0.88 | BTK (0.71) | BTKEGFRLCKITK | |
| SCHEMBL18269161 | 0.86 | BTK (0.64) | BTKEGFRLCKITK | |
| SCHEMBL18269037 | 0.85 | BTK (0.58) | BTKEGFRLCKITK | |
| SCHEMBL18269157 | 0.85 | BTK (0.58) | BTKEGFRLCKKCNH2 | |
| SCHEMBL18268843 | 0.85 | BTK (0.70) | BTKEGFRLCKITK | |
| SCHEMBL18268845 | 0.82 | BTK (0.60) | BTKEGFRLCKITK | |
| SCHEMBL15613536 | 0.81 | BTK (0.50) | BTKEGFRLCKITKFGFR1 | |
| SCHEMBL15613564 | 0.80 | BTK (0.49) | BTKEGFRLCKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179210-A1 | Inhibitors of the TEC Kinase Enzyme Family | PHARMASCIENCE INC. (CA) | 2018-06-28 | — | — | US | disclosed |
| WO-2016187723-A1 | INHIBITORS OF THE TEC KINASE ENZYME FAMILY | PHARMASCIENCE INC. (CA) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179210-A1 | Inhibitors of the TEC Kinase Enzyme Family | TEC, BTK, LCK | BTK 2/4885EGFR 671/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.